APA (7th ed.) Citation

Roviello, G., & Antonuzzo, L. (2026). Re: Ruben Raychaudhuri, Ali Raza Khaki, Mary W. Redman, et al. Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive Bladder Cancer: A Phase 2 Trial. Eur Urol. 2025;88:559–563. European Urology, 89(3), e73. https://doi.org/10.1016/j.eururo.2025.08.033

Chicago Style (17th ed.) Citation

Roviello, Giandomenico, and Lorenzo Antonuzzo. "Re: Ruben Raychaudhuri, Ali Raza Khaki, Mary W. Redman, Et Al. Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive Bladder Cancer: A Phase 2 Trial. Eur Urol. 2025;88:559–563." European Urology 89, no. 3 (2026): e73. https://doi.org/10.1016/j.eururo.2025.08.033.

MLA (9th ed.) Citation

Roviello, Giandomenico, and Lorenzo Antonuzzo. "Re: Ruben Raychaudhuri, Ali Raza Khaki, Mary W. Redman, Et Al. Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive Bladder Cancer: A Phase 2 Trial. Eur Urol. 2025;88:559–563." European Urology, vol. 89, no. 3, 2026, p. e73, https://doi.org/10.1016/j.eururo.2025.08.033.